Compare CBIO & CSV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBIO | CSV |
|---|---|---|
| Founded | 2003 | 1991 |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | | Other Consumer Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.8M | 643.0M |
| IPO Year | N/A | 1996 |
| Metric | CBIO | CSV |
|---|---|---|
| Price | $18.13 | $38.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $26.67 | ★ $59.00 |
| AVG Volume (30 Days) | ★ 269.6K | 93.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.92% |
| EPS Growth | N/A | ★ 54.76 |
| EPS | N/A | ★ 0.84 |
| Revenue | N/A | ★ $417,440,000.00 |
| Revenue This Year | N/A | $7.35 |
| Revenue Next Year | $279.20 | $3.87 |
| P/E Ratio | ★ N/A | $45.02 |
| Revenue Growth | N/A | ★ 3.28 |
| 52 Week Low | $8.72 | $37.11 |
| 52 Week High | $27.41 | $52.10 |
| Indicator | CBIO | CSV |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 28.96 |
| Support Level | $16.31 | N/A |
| Resistance Level | $21.60 | $44.93 |
| Average True Range (ATR) | 1.78 | 1.44 |
| MACD | -0.30 | -0.42 |
| Stochastic Oscillator | 27.80 | 13.73 |
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.